Clinical trial
The Safety and Effectiveness of SPC3 in HIV-1 Infected Patients
NCT00002363 · Columbia Research Laboratories, Industry · Completed
Key facts
| NCT number | NCT00002363 |
|---|---|
| Title | The Safety and Effectiveness of SPC3 in HIV-1 Infected Patients |
| Official title | Study of the Safety and Effects of Two Doses of SPC3, Administered Daily Intravenously in HIV-1 Seropositive Patients |
| Lead sponsor | Columbia Research Laboratories, Industry |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | HIV Infections |
| Intervention type | Drug |
| Interventions | Peptide Construction 3, Synthetic |
| Enrollment | 20 |
| First posted | Aug 31, 2001 |
| Last update posted | Jun 24, 2005 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: